Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
October 18, 2025Confinia CephalalgicaOpen Access

PO-91 | Real-world evidence of CGRP dual blockade: clinical and biomarker insights from combined therapy in chronic migraine

View Full Paper
Ask AI
Bookmark
Share

Authors

SCSocietà Italiana per lo Studio delle Cefalee

Discussion

Loading...

Member takes

Overview

Observational analysis shows greater reductions in migraine days and headache intensity with dual blockade therapy, suggesting enhanced efficacy over monotherapy.

Key Points

  • The combination therapy group showed greater reductions in monthly migraine days and disability scores compared to the monotherapy group.
  • Responders, defined as those remaining migraine-free for 6 consecutive weeks, were more frequent in the combination cohort.
  • Both treatment approaches were well tolerated, with no serious adverse events reported among participants.
  • Chronic migraine may be better managed with a multimodal strategy that combines onabotulinumtoxinA and CGRP receptor antagonists.

Cite This Study

Società Italiana per lo Studio delle Cefalee (2025) studied this question.

synapsesocial.com/papers/68f35bfc73f0a7d050f47ec0https://doi.org/10.4081/cc.2025.15915
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Combination preventive therapy with onabotulinumtoxinA and atogepant for chronic migraine: A 24-week, prospective, real-world evaluation (SYNERGY study)2025
  2. 2Synergism of Anti-CGRP Monoclonal Antibodies and OnabotulinumtoxinA in the Treatment of Chronic Migraine: A Real-World Retrospective Chart Review2024 · 4 citations
  3. 3Effectiveness of Onabotulinumtoxin-A in Patients with Chronic Migraine and Previous CGRP-mAb Treatment Failure: A Multicentre 6-Month Real-World Experience2026
  4. 4Effectiveness and tolerability of atogepant as preventive treatment in resistant individuals with chronic migraine: Six-month real-world evidence2025
  5. 5Safety, tolerability, and efficacy of atogepant added to onabotulinumtoxinA for the preventive treatment of chronic migraine: A phase 3, multicenter, 24-week, open-label study2026